FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887535250> ?p ?o ?g. }

• W2887535250 abstract "Fimasartan (Kanarb; Boryung Pharmaceutical Co., Ltd., Seoul, Republic of Korea) is a non-protein angiotensin II receptor blocker that selectively blocks the AT1 receptor. No prior large-scale study has investigated the impact of demographics, disease, treatment, and clinical characteristics on medication satisfaction and quality of life in Korean hypertensive patients. Additionally, it is unclear whether increased medication compliance affects the achievement of hypertension treatment objectives.This was a multicenter, non-interventional, open-label and 8-week switching study. This study was divided into 2 steps. STEP I was a cross-sectional study composed entirely of hypertensive patients undergoing treatment and STEP II was a prospective observational study of hypertensive patients switching to fimasartan. A total of 12,244 and 2023 patients were analyzed in the STEP I and STEP II groups, respectively. In STEP I, we investigated demographics, clinical, disease, and treatment characteristics at the registration point and then analyzed medication satisfaction, patient compliance, and quality of life. In STEP II, the patients who switched to fimasartan were followed up for 8 weeks, and the data analyzed included changes in medication effects, satisfaction, compliance, and adverse events.Some baseline characteristics, such as sex, body mass index, region of residence, educational level, and income level, affected the quality of life and medication duration in hypertensive patients. At 4 and 8 weeks, 62.5 and 69.9% of patients, respectively, reached their target blood pressure. The medication satisfaction scores were increased 4.0 ± 1.2, 5.1 ± 1.1, and 5.4 ± 1.0 at baseline, 4 weeks, and 8 weeks, respectively, and the difference was statistically significant (p < 0.0001). Most patients (76.4%) who changed from prior antihypertensive drug to fimasartan were not satisfied with conventional antihypertensive drugs (e.g., lack of efficacy). Among 2183 patients, 234 adverse events occurred in 151 (6.9%) and 50 adverse drug reactions occurred in 39 (1.8%).The demographic, clinical, disease, and treatment characteristics of hypertensive patients were investigated in this study. After switching to fimasartan, blood pressure was significantly decreased and patient satisfaction was improved. Fimasartan treatment was well tolerated and safe in hypertensive patients in Korea.Trial registration.ClinicalTrials.gov Identifier: (NCT02394392)." @default.
• W2887535250 created "2018-08-22" @default.
• W2887535250 creator A5032222390 @default.
• W2887535250 creator A5042148107 @default.
• W2887535250 creator A5057521801 @default.
• W2887535250 creator A5077080004 @default.
• W2887535250 creator A5091074457 @default.
• W2887535250 date "2018-09-01" @default.
• W2887535250 modified "2023-09-23" @default.
• W2887535250 title "Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)" @default.
• W2887535250 cites W1964334181 @default.
• W2887535250 cites W2093854370 @default.
• W2887535250 cites W2097619721 @default.
• W2887535250 cites W2139584372 @default.
• W2887535250 cites W2165927787 @default.
• W2887535250 cites W2414018945 @default.
• W2887535250 cites W2760799672 @default.
• W2887535250 cites W3129860401 @default.
• W2887535250 doi "https://doi.org/10.1186/s40885-018-0096-2" @default.
• W2887535250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6119343" @default.
• W2887535250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30186623" @default.
• W2887535250 hasPublicationYear "2018" @default.
• W2887535250 type Work @default.
• W2887535250 sameAs 2887535250 @default.
• W2887535250 citedByCount "1" @default.
• W2887535250 countsByYear W28875352502021 @default.
• W2887535250 crossrefType "journal-article" @default.
• W2887535250 hasAuthorship W2887535250A5032222390 @default.
• W2887535250 hasAuthorship W2887535250A5042148107 @default.
• W2887535250 hasAuthorship W2887535250A5057521801 @default.
• W2887535250 hasAuthorship W2887535250A5077080004 @default.
• W2887535250 hasAuthorship W2887535250A5091074457 @default.
• W2887535250 hasBestOaLocation W28875352501 @default.
• W2887535250 hasConcept C126322002 @default.
• W2887535250 hasConcept C141071460 @default.
• W2887535250 hasConcept C142052008 @default.
• W2887535250 hasConcept C142724271 @default.
• W2887535250 hasConcept C159110408 @default.
• W2887535250 hasConcept C188816634 @default.
• W2887535250 hasConcept C197934379 @default.
• W2887535250 hasConcept C23131810 @default.
• W2887535250 hasConcept C2775944032 @default.
• W2887535250 hasConcept C2779951463 @default.
• W2887535250 hasConcept C71924100 @default.
• W2887535250 hasConcept C84393581 @default.
• W2887535250 hasConceptScore W2887535250C126322002 @default.
• W2887535250 hasConceptScore W2887535250C141071460 @default.
• W2887535250 hasConceptScore W2887535250C142052008 @default.
• W2887535250 hasConceptScore W2887535250C142724271 @default.
• W2887535250 hasConceptScore W2887535250C159110408 @default.
• W2887535250 hasConceptScore W2887535250C188816634 @default.
• W2887535250 hasConceptScore W2887535250C197934379 @default.
• W2887535250 hasConceptScore W2887535250C23131810 @default.
• W2887535250 hasConceptScore W2887535250C2775944032 @default.
• W2887535250 hasConceptScore W2887535250C2779951463 @default.
• W2887535250 hasConceptScore W2887535250C71924100 @default.
• W2887535250 hasConceptScore W2887535250C84393581 @default.
• W2887535250 hasIssue "1" @default.
• W2887535250 hasLocation W28875352501 @default.
• W2887535250 hasLocation W28875352502 @default.
• W2887535250 hasLocation W28875352503 @default.
• W2887535250 hasLocation W28875352504 @default.
• W2887535250 hasOpenAccess W2887535250 @default.
• W2887535250 hasPrimaryLocation W28875352501 @default.
• W2887535250 hasRelatedWork W1980510366 @default.
• W2887535250 hasRelatedWork W2011551623 @default.
• W2887535250 hasRelatedWork W2038512849 @default.
• W2887535250 hasRelatedWork W2043308783 @default.
• W2887535250 hasRelatedWork W2044640544 @default.
• W2887535250 hasRelatedWork W2053662552 @default.
• W2887535250 hasRelatedWork W2064337552 @default.
• W2887535250 hasRelatedWork W2080341688 @default.
• W2887535250 hasRelatedWork W2405636340 @default.
• W2887535250 hasRelatedWork W2504479046 @default.
• W2887535250 hasRelatedWork W2582387971 @default.
• W2887535250 hasRelatedWork W2605567389 @default.
• W2887535250 hasRelatedWork W2755094416 @default.
• W2887535250 hasRelatedWork W2802068364 @default.
• W2887535250 hasRelatedWork W2889846954 @default.
• W2887535250 hasRelatedWork W2954485850 @default.
• W2887535250 hasRelatedWork W3006884194 @default.
• W2887535250 hasRelatedWork W3015082070 @default.
• W2887535250 hasRelatedWork W3030513959 @default.
• W2887535250 hasRelatedWork W2468557666 @default.
• W2887535250 hasVolume "24" @default.
• W2887535250 isParatext "false" @default.
• W2887535250 isRetracted "false" @default.
• W2887535250 magId "2887535250" @default.
• W2887535250 workType "article" @default.